IHE

iShares U.S. Pharmaceuticals ETF

• Benzinga·05/20 17:09

  Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery

• Benzinga·01/28 17:07

  UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs

• Benzinga·01/16 07:30

  Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'

• Benzinga·12/19/2025 20:17

  Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts

• Benzinga·11/24/2025 17:06

  Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

• Benzinga·11/15/2025 14:31

  Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

• Benzinga·11/12/2025 11:22

  Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

• Benzinga·10/30/2025 20:04

  Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

• Benzinga·09/29/2025 16:06

  Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

• Benzinga·09/29/2025 07:20

  Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

• Benzinga·09/08/2025 05:49

  Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing

• Benzinga·08/01/2025 08:12

  Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'

• Benzinga·07/29/2025 02:37

  Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'

• Benzinga·07/26/2025 12:31

  Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

• Benzinga·07/16/2025 07:22

  Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'